The landscape of addiction treatment is experiencing a fascinating transformation, with psychedelic-assisted therapies emerging as a promising frontier. This approach, once considered taboo, is gaining traction in scientific circles and showing potential for treating various substance use disorders. Understanding the nuances of this evolution is crucial for enhancing your treatment offerings.

After decades of prohibition, psychedelics are undergoing a research renaissance. Substances like psilocybin (from "magic mushrooms"), MDMA, and ketamine are being studied for their therapeutic potential in treating addiction, depression, and PTSD. For instance, a recent review of randomized controlled trials found that psilocybin significantly reduced heavy drinking days for individuals with alcohol use disorder. Additionally, a 2017 study has found found that psychedelic use was associated with a 40% reduced risk of past-year opioid misuse and 27% reduced risk of past year opioid dependence among those with opioid use disorder.

Psychedelic-assisted treatment involves several stages: assessment and preparation, dosing, and integration. During the preparation phase, patients learn about........

© Psychology Today